Recombinant envelope vaccine against flavivirus infection

US6432411B1 · kind B1 · utility

Assignee

• Hawaii Biotechnology Group, Inc. · US

Inventors

• John Ivy · College Station, US
• Gary Bignami · Waialua, US
• Michael McDonell · Bogart, US
• David E. Clements · Honolulu, US
• Beth-Ann Griswold Coller · Woluwe-Saint-Lambert - Sint-Lambrechts-Woluwe, BE

Key dates

• Filing date: Jul 13, 1999
• Grant date: Aug 13, 2002
• Expiry date: Jul 13, 2019

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A vaccine contains at least one Drosophila cell-secreted, recombinantly-produced form of a truncated Flavivirus envelope glycoprotein, as an active ingredient, and an adjuvant, as a critical component of the vaccine. The adjuvant is an immunomodulating agent having an iscom-like structure and comprising within the iscom-like structure at least one lipid and at least one saponin, and a pharmaceutically acceptable vehicle. Such a vaccine protects a subject against infection by a Flavivirus.